81
Participants
Start Date
April 30, 2013
Primary Completion Date
August 8, 2016
Study Completion Date
October 27, 2016
Adalimumab
Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
Buffalo Medical Group, Buffalo
University of Pennsylvania, Philadelphia
National Heart, Lung, and Blood Institute, Bethesda
Menter Dermatology Research Institute, Dallas
Center for Clinical Studies, Houston
University of Colorado, Denver
University of Utah, Salt Lake City
University of California, Davis Health System, Sacramento
Oregon Health & Science University, Portland
Collaborators (1)
AbbVie
INDUSTRY
University of Pennsylvania
OTHER